

Shiv Srivastava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1923602/publications.pdf>

Version: 2024-02-01

52
papers

3,296
citations

318942

23
h-index

274796

44
g-index

54
all docs

54
docs citations

54
times ranked

4349
citing authors

#	ARTICLE	IF	CITATIONS
1	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. <i>Scientific Reports</i> , 2022, 12, 5404.	1.6	10
2	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. <i>Nature Communications</i> , 2022, 13, 1361.	5.8	8
3	Prognostic features of Annexin A2 expression in prostate cancer. <i>Pathology</i> , 2021, 53, 205-213.	0.3	15
4	Abstract 2074: Germline mutation landscape of all DNA repair genes in African American prostate cancer patients. , 2021, , .		0
5	Abstract 2526: PMEPA1 gene isoforms indicated aggressive disease progression in non-prostate solid tumors. , 2021, , .		0
6	New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1703-1709.	1.3	5
7	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	0.9	32
8	Detection of Head and Neck Cancer Based on Longitudinal Changes in Serum Protein Abundance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1665-1672.	1.1	16
9	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 406-410.	2.0	45
10	<i>PMEPA1</i> gene isoforms to indicate disease progression in solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16580-e16580.	0.8	1
11	Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF- β 2 from growth suppressor to growth and metastasis promoter through TMEPA1/PMEPA1 in triple negative breast cancer. <i>Genes and Cancer</i> , 2019, 10, 134-149.	0.6	24
12	Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. <i>European Urology Focus</i> , 2018, 4, 818-824.	1.6	16
13	Ethnicity and ERG frequency in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 125-131.	1.9	28
14	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1255.	1.8	50
15	Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>European Urology</i> , 2017, 71, 692.	0.9	1
16	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. <i>Scientific Reports</i> , 2017, 7, 1109.	1.6	17
17	TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. <i>American Journal of Epidemiology</i> , 2017, 186, 1352-1361.	1.6	60
18	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	57

#	ARTICLE	IF	CITATIONS
19	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. <i>Genes and Cancer</i> , 2017, 7, 394-413.	0.6	14
20	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 810-822.	1.2	45
21	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Genes Genomic Prostate Score. <i>Urology</i> , 2016, 89, 69-75.	0.5	43
22	Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. <i>Oncotarget</i> , 2016, 7, 22791-22806.	0.8	19
23	Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors. <i>Journal of Cancer</i> , 2015, 6, 490-501.	1.2	4
24	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. <i>European Urology</i> , 2015, 68, 123-131.	0.9	281
25	ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. <i>Molecular and Clinical Oncology</i> , 2015, 3, 23-30.	0.4	8
26	ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 368-379.	1.5	12
27	Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. <i>Journal of Translational Medicine</i> , 2015, 13, 54.	1.8	23
28	Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. <i>Oncotarget</i> , 2015, 6, 15137-15149.	0.8	29
29	Methylation of the <i>PMEPA1</i> gene, a negative regulator of the androgen receptor in prostate cancer. <i>Epigenetics</i> , 2014, 9, 918-927.	1.3	25
30	A long noncoding RNA connects c-Myc to tumor metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18697-18702.	3.3	258
31	Predominance of ERG-negative high-grade prostate cancers in African American men. <i>Molecular and Clinical Oncology</i> , 2014, 2, 982-986.	0.4	24
32	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. <i>Genes and Cancer</i> , 2014, 5, 273-284.	0.6	8
33	Clinical potential of the ERG oncoprotein in prostate cancer. <i>Nature Reviews Urology</i> , 2012, 9, 131-137.	1.9	56
34	The center for prostate disease research (CPDR): A multidisciplinary approach to translational research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 562-569.	0.8	27
35	Identification of an Orphan 7TM Receptor PSGR as a Functional Intracellular GPCR. <i>FASEB Journal</i> , 2008, 22, 722.6.	0.2	0
36	Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. <i>International Journal of Cancer</i> , 2001, 92, 322-328.	2.3	96

#	ARTICLE	IF	CITATIONS
37	A novel human cancer culture model for the study of prostate cancer. <i>Oncogene</i> , 2001, 20, 8036-8041.	2.6	31
38	p53-dependent induction of heat shock protein 27 (HSP27) expression. <i>International Journal of Cancer</i> , 2000, 88, 191-194.	2.3	21
39	Allelic loss on chromosome 6Q in primary prostate cancer. , 1999, 84, 331-335.		46
40	Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. <i>Oncogene</i> , 1998, 16, 265-272.	2.6	115
41	Statistical Modeling Using Preoperative Prognostic Variables in Predicting Extracapsular Extension and Progression after Radical Prostatectomy for Prostate Cancer. <i>Military Medicine</i> , 1998, 163, 615-619.	0.4	12
42	Synchronous Bilateral Testicular Tumour: Nonseminomatous Germ Cell Tumours and Contralateral Benign Tumours. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 389-392.	1.4	24
43	Mutations of the p16 gene product are rare in prostate cancer. , 1997, 30, 188-194.		28
44	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 1997, 79, 952-962.	2.0	72
45	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377-382.		46
46	Mutations of the p16 gene product are rare in prostate cancer. , 1997, 30, 188.		2
47	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. <i>Cancer</i> , 1997, 79, 952-962.	2.0	4
48	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377.		1
49	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377.		1
50	Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 1996, 156, 1511-1516.	0.2	218
51	Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer. <i>Journal of Urology</i> , 1995, 154, 414-421.	0.2	161
52	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Liê€Fraumeni syndrome. <i>Nature</i> , 1990, 348, 747-749.	18.7	1,156